ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,221 to 4,240 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Fluid Restriction Group vs Standard-care: All-cause Mortality at 1-year After Randomisation385 of 750

383 of 767

1.4 points

-3.6 to 6.4

1,517NCT03668236

The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial

Primary Enrollment Group vs 38 mm Length Sub-Study: serious adverse events509 of 1,402

71 of 114

-26.0 points

-34.7 to -16.5

1,516NCT00726453

The Medtronic RESOLUTE US Clinical Trial

Olive Oil Capsule vs Omega-3 Fatty Acid Capsules: Any First Post-op Atrial Fibrillation or Flutter (AF)233 of 758

227 of 758

0.8 points

-3.8 to 5.4

1,516NCT00970489

Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation

Olive Oil Capsule vs Omega-3 Fatty Acid Capsules: serious adverse events147 of 758

136 of 758

1.5 points

-2.5 to 5.4

1,516NCT00970489

Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation

Restrictive Fluids vs Liberal Fluids: Development of ARDS19 of 757

20 of 758

-0.1 points

-1.8 to 1.5

1,515NCT03434028

Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis

Boostrix Group vs Adacel Group: Number of Subjects With Anti-diphtheria (Anti-D) Antibody Concentrations Greater Than or Equal to (≥) Protocol Specified Cut-off967 of 1,010

489 of 504

-1.3 points

-3.1 to 0.9

1,514NCT00489970

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

Information vs Usual Care: Advance Care Planning Billing23 of 770

11 of 743

1.5 points

-0.0 to 3.1

1,513NCT04852055

Effect of an Advance Care Planning Intervention

Information vs Usual Care: Hospitalization113 of 770

110 of 743

-0.1 points

-3.7 to 3.4

1,513NCT04852055

Effect of an Advance Care Planning Intervention

cSBA - New England, USA vs Control - New England, USA: Any Risky Riding or Driving at 3 Months - New England, USA88 of 758

150 of 754

-8.3 points

-11.9 to -4.6

1,512NCT00227877

Screening and Brief Advice to Reduce Teen Substance Use

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8873 of 1,012

388 of 500

8.7 points

4.6 to 13.0

1,512NCT02940860

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 832 of 1,011

4 of 500

2.4 points

0.8 to 3.7

1,511NCT02940860

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8484 of 1,009

225 of 502

3.1 points

-2.2 to 8.4

1,511NCT02940886

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8687 of 1,009

340 of 502

0.4 points

-4.6 to 5.4

1,511NCT02940886

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

QMF149 Twisthaler® 500/400 vs Mometasone Twisthaler®: Patients With Asthma Exacerbations That Required Treatment With Systemic Corticosteroids124 of 749

171 of 759

-6.0 points

-10.0 to -2.0

1,508NCT00941798

Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

QMF149 Twisthaler® 500/400 vs Mometasone Twisthaler®: Cumulative Incidence of the First Serious Asthma Exacerbation Resulting in Hospitalization, Intubation or Death.2 of 749

6 of 759

-0.5 points

-1.5 to 0.3

1,508NCT00941798

Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

QMF149 Twisthaler® 500/400 vs Mometasone Twisthaler®: Number of Patients With at Least One Asthma Worsening Post-baseline533 of 749

637 of 759

-12.8 points

-16.9 to -8.6

1,508NCT00941798

Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

QMF149 Twisthaler® 500/400 vs Mometasone Twisthaler®: serious adverse events30 of 749

44 of 759

-1.8 points

-4.0 to 0.4

1,508NCT00941798

Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

150 µg Corifollitropin Alfa vs 200 IU recFSH: serious adverse events35 of 755

30 of 751

0.6 points

-1.5 to 2.7

1,506NCT00696800

A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)

Standard of Care Plus (SCP) vs Collaborative Care/Stepped Care (CC/SC): Number of Participants With Controlled Blood Pressure462 of 750

442 of 754

3.0 points

-2.0 to 7.9

1,504NCT02674464

Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project)

Intervention vs Control: deaths from any cause8 of 1,000

4 of 503

0.0 points

-1.3 to 0.9

1,503NCT01800201

Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=212"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=212

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03668236-0de99219",
        "title": "Fluid Restriction Group vs Standard-care: All-cause Mortality at 1-year After Randomisation",
        "summary": "385 of 750 against 383 of 767; risk difference 1.4 points, 95% interval -3.6 to 6.4; NCT03668236, The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial",
        "record": "/library/comparisons/NCT03668236-0de99219",
        "nct_id": "NCT03668236",
        "kind": "outcome",
        "participants": 1517,
        "risk_difference": {
          "value": 0.01398522381573225,
          "lower": -0.03625425849769667,
          "upper": 0.06412353122718675
        },
        "group_1": "385 of 750",
        "group_2": "383 of 767",
        "difference": "1.4 points",
        "interval": "-3.6 to 6.4",
        "trial_title": "The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial"
      },
      {
        "id": "NCT00726453-sae",
        "title": "Primary Enrollment Group vs 38 mm Length Sub-Study: serious adverse events",
        "summary": "509 of 1402 against 71 of 114; risk difference -26.0 points, 95% interval -34.7 to -16.5; NCT00726453, The Medtronic RESOLUTE US Clinical Trial",
        "record": "/library/comparisons/NCT00726453-sae",
        "nct_id": "NCT00726453",
        "kind": "serious-adverse-events",
        "participants": 1516,
        "risk_difference": {
          "value": -0.2597542358034888,
          "lower": -0.3469436696170688,
          "upper": -0.1646626056137923
        },
        "group_1": "509 of 1,402",
        "group_2": "71 of 114",
        "difference": "-26.0 points",
        "interval": "-34.7 to -16.5",
        "trial_title": "The Medtronic RESOLUTE US Clinical Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=213",
  "request_id": "SWAYlhclMjYEG_Vk"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?